Clinical trial · Interventional
Cancer Genetic Testing in Ethnic Populations
GEMINI - Cancer Genetic Testing in Ethnic Populations
NCT04475640CI-TRIAL-00107091recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. The information from this study may provide an opportunity for cancer risk stratification and individualized screening in these ethnic populations.
Conditions
Conditions (11)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Carcinoma | Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Carcinoma of Unknown Primary | Carcinoma of Unknown Primary | ONTOLOGY_EXACT | 0.98 |
| Central Nervous System Carcinoma | Central Nervous System Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Digestive System Carcinoma | Digestive System Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Genitourinary System Carcinoma | Genitourinary System Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Head and Neck Carcinoma | Head and Neck Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Malignant Brain Neoplasm | Malignant Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Malignant Female Reproductive System Neoplasm | Malignant Female Reproductive System Neoplasm | ONTOLOGY_EXACT |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biospecimen Collection | Procedure | — | UNRESOLVED |
| Genetic Testing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Screening (biospecimen collection)
- description
- Patients undergo collection of blood or saliva sample for genetic testing.
- interventionNames
- Procedure: Biospecimen Collection
- Other: Genetic Testing
Primary outcomes (4)
- measure
- Prevalence of pathogenic germline mutations in enrolled patients within each cancer site
- timeFrame
- Study completion (2 years)
- description
- Will identify the prevalence of pathogenic germline mutations in enrolled patients within each cancer site, age (\< 60 years old versus (vs.) \>= 60 years old), and stage (early vs. advanced) via descriptive statistics.
- measure
- Prevalence of positive pathogenic germline mutations
- timeFrame
- Study completion (2 years)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients at least 18 years of age * Individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (CNS)/brain, head/neck, musculoskeletal or cancer of unknown primary; and presenting to Mayo Clinic (MC Arizona or MC Florida) for clinical management/treatment; and patients receive genetic testing as described above * Self-identified as being from various ethnic populations including Hispanic/Latino, Native American/Alaskan, African American (including of African descent), Asian and other European populations * Blood collection is feasible (health, access and/or tolerability) for requested blood sample(s) * Individuals have agreed to participate and signed the study informed consent form Exclusion Criteria: * Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic and available for review by the research coordinator at time of consent * Past or current history of hematological cancer (including leukemias, multiple myeloma) * All bone marrow transplants
References
Publications (0)
Data not yet available
No reference posted for this study.